rs10507540 - LRRC63
Magnitude 4.5 · 1 study on file
Reported associations
-
Large-scale pharmacogenomic study of sulfonylureas and the QT, JT, and QRS intervals: CHARGE Pharmacogenomics Working Group - Unknown journal (n.d.) · Unknown authors · PubMed 27958378
ABSTRACT: Sulfonylureas, a commonly-used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In eleven ethnically diverse cohorts that included 71 857 European, African American, and Hispanic/Latino ancestry individuals with repeated measures of medication use and electrocardiogram (ECG) measurements, we conducted a pharmacogenomic genome-wide association study of sulfonylurea use and three ECG phenotypes: QT, JT, and QRS intervals. In ancestry-specific meta-analyses, 8 novel pharmacogenomic loci met the threshold for genome-wide significance (P < 5 x 10−8), and a pharmacokinetic variant i
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
LRRC63 variant and sulfonylurea cardiac interaction Moderate
LRRC63 rs10507540 carriers show altered QRS interval when taking sulfonylureas, potentially affecting cardiac conduction and arrhythmia risk
Discuss your genetic status and current or planned sulfonylurea use with your healthcare provider
Screening
-
baseline and periodic EKG if on sulfonylureas Moderate
LRRC63-sulfonylurea treatment interaction alters QRS interval, warranting cardiac electrical monitoring
Obtain EKG before initiating sulfonylureas and periodically per cardiologist guidance